Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CABA Stock Summary
Top 10 Correlated ETFs
CABA
In the News
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024.
Buy Cabaletta Bio's Promising SLE Treatment
Cabaletta Bio is a biotech company with promising CARTA and CAART therapies for autoimmune diseases. Their main research project, CABA-201, targets patients suffering from SLE, opening up a huge market with significant revenue potential. The company is well-capitalized and has a cash runway that extends beyond 2025, making it a good long-term investment.
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy
Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug Administration said it was investigating cancer risks potentially associated with all currently approved products in the class.
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in three upcoming investor conferences in November:
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:
Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?
Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a validated cell therapy approach, rather than oncology, has been a key factor in its success. Cabaletta's cell therapy CABA-201 targeting Lupus Nephritis has had its MoA validated by an academic study, leading to increased investor interest and a rise in share price.
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
The 7 Most Promising Momentum Stocks to Own Now
Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum investing hinges on the principle that assets that have performed well recently will continue to do so in the near future.
CABA Financial details
CABA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.76 | -1.4 | -13.68 | -2.41 | 0 | |
Operating cash flow per share | -2.93 | -1.16 | -10.25 | -2.15 | 0 | |
Free cash flow per share | -3.06 | -1.18 | -10.6 | -2.27 | 0 | |
Cash per share | 24.9 | 4.69 | 36.72 | 4.95 | 0 | |
Book value per share | 25.29 | 4.73 | 35.44 | 4.85 | 0 | |
Tangible book value per share | 25.29 | 4.73 | 35.44 | 4.85 | 0 | |
Share holders equity per share | 25.29 | 4.73 | 35.44 | 4.85 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0.18 | 0 | |
Market cap | 76.41M | 288.85M | 12.62M | 199.19M | 0 | |
Enterprise value | -59.8M | 187.42M | -109.61M | 122.72M | -188.22M | |
P/E ratio | -5.06 | -8.89 | -0.28 | -3.84 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.76 | -10.79 | -0.37 | -4.29 | 0 | |
PFCF ratio | -4.56 | -10.54 | -0.36 | -4.08 | 0 | |
P/B Ratio | 0.55 | 2.64 | 0.11 | 1.91 | 0 | |
PTB ratio | 0.55 | 2.64 | 0.11 | 1.91 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 3.2 | -5.54 | 2.37 | -2.27 | 2.52 | |
EV to operating cash flow | 3.73 | -7 | 3.21 | -2.65 | 3.51 | |
EV to free cash flow | 3.57 | -6.84 | 3.11 | -2.51 | 3.47 | |
Earnings yield | -0.2 | -0.11 | -3.61 | -0.26 | 0 | |
Free cash flow yield | -0.22 | -0.09 | -2.8 | -0.25 | 0 | |
Debt to equity | 0 | 0 | 0 | 0.05 | 0.02 | |
Debt to assets | 0 | 0 | 0 | 0.04 | 0.02 | |
Net debt to EBITDA | 7.29 | 3 | 2.64 | 1.41 | 2.52 | |
Current ratio | 44.66 | 21.92 | 14.86 | 11.47 | 15.29 | |
Interest coverage | 0 | 0 | 0 | 45.96 | 0 | |
Income quality | 0.95 | 0.8 | 0.74 | 0.88 | 0.79 | |
Dividend Yield | 0.13 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.67 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.02 | 0.03 | 0.05 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -6.66 | -1.79 | -1.59 | -2.08 | -0.48 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 39.63 | 12.23 | 104.43 | 16.21 | 0 | |
ROIC | -0.12 | -0.3 | -0.39 | -0.46 | -0.3 | |
Return on tangible assets | -0.11 | -0.28 | -0.36 | -0.44 | -0.27 | |
Graham Net | 24.33 | 4.47 | 34.2 | 4.37 | 0 | |
Working capital | 137.41M | 108.36M | 116.16M | 99.35M | 228.5M | |
Tangible asset value | 138.32M | 109.54M | 117.96M | 104.52M | 236.2M | |
Net current asset value | 137.41M | 108.36M | 116.16M | 96.39M | 227.04M | |
Invested capital | 0 | 0 | 0 | 0.05 | 0.02 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 761.5K | 1.08M | 1.79M | 2.4M | 3.51M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 3.23K | 1.28K | 1.16K | 244.03 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.11 | 0.28 | 0.31 | 1.5 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.11 | -0.3 | -0.39 | -0.5 | -0.29 | |
Capex per share | -0.13 | -0.03 | -0.35 | -0.11 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.38 | -0.51 | -0.42 | -0.39 | -0.39 | |
Operating cash flow per share | -0.34 | -0.41 | -0.36 | -0.32 | -0.3 | |
Free cash flow per share | -0.38 | -0.42 | -0.37 | -0.32 | -0.3 | |
Cash per share | 2.96 | 3.62 | 2.65 | 4.73 | 3.9 | |
Book value per share | 2.96 | 3.55 | 2.59 | 4.67 | 3.82 | |
Tangible book value per share | 2.96 | 3.55 | 2.59 | 4.67 | 3.82 | |
Share holders equity per share | 2.96 | 3.55 | 2.59 | 4.67 | 3.82 | |
Interest debt per share | 0.01 | 0.16 | 0.1 | 0.11 | 0.1 | |
Market cap | 18.86M | 272.37M | 293.16M | 481.7M | 640.92M | |
Enterprise value | -42.3M | 195.9M | 203.99M | 357.82M | 529.69M | |
P/E ratio | -0.43 | -4.58 | -4.97 | -8.31 | -9.74 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -1.9 | -22.45 | -23.25 | -40.52 | -50.85 | |
PFCF ratio | -1.71 | -21.88 | -22.57 | -40.32 | -50.59 | |
P/B Ratio | 0.22 | 2.61 | 3.2 | 2.77 | 3.98 | |
PTB ratio | 0.22 | 2.61 | 3.2 | 2.77 | 3.98 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 3.71 | -12.02 | -12.3 | -23.06 | -28.37 | |
EV to operating cash flow | 4.27 | -16.15 | -16.18 | -30.1 | -42.03 | |
EV to free cash flow | 3.84 | -15.74 | -15.71 | -29.95 | -41.81 | |
Earnings yield | -0.59 | -0.05 | -0.05 | -0.03 | -0.03 | |
Free cash flow yield | -0.58 | -0.05 | -0.04 | -0.02 | -0.02 | |
Debt to equity | 0 | 0.05 | 0.05 | 0.02 | 0.03 | |
Debt to assets | 0 | 0.04 | 0.05 | 0.02 | 0.02 | |
Net debt to EBITDA | 5.36 | 4.69 | 5.37 | 7.98 | 5.96 | |
Current ratio | 15.2 | 11.47 | 10.29 | 20.94 | 15.65 | |
Interest coverage | -33.56 | 32.54 | 15.39 | 0 | 0 | |
Income quality | 0.87 | 0.77 | 0.8 | 0.82 | 0.77 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.11 | 0.03 | 0.03 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -3.01 | -0.88 | -1.04 | -0.15 | -0.18 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.04 | 6.35 | 4.92 | 6.39 | 5.8 | |
ROIC | -0.13 | -0.13 | -0.16 | -0.09 | -0.11 | |
Return on tangible assets | -0.12 | -0.13 | -0.14 | -0.08 | -0.09 | |
Graham Net | 2.76 | 3.2 | 2.31 | 4.44 | 3.61 | |
Working capital | 82.37M | 99.35M | 86.43M | 169.09M | 155.56M | |
Tangible asset value | 85.87M | 104.52M | 91.65M | 174.14M | 160.92M | |
Net current asset value | 82.37M | 96.39M | 83.94M | 167.08M | 153.81M | |
Invested capital | 0 | 0.05 | 0.05 | 0.02 | 0.03 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.89M | 1.9M | 3.21M | 3.15M | 2.98M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 330.5 | 77.4 | 435.68 | 252.93 | 917.75 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.27 | 1.16 | 0.21 | 0.36 | 0.1 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.14 | -0.16 | -0.08 | -0.1 | |
Capex per share | -0.04 | -0.01 | -0.01 | 0 | 0 |
CABA Frequently Asked Questions
What is Cabaletta Bio, Inc. stock symbol ?
Cabaletta Bio, Inc. is a US stock , located in Philadelphia of Pa and trading under the symbol CABA
Is Cabaletta Bio, Inc. buy or a sell ?